A 12-week maintenance therapy with a new prepared viscous budesonide in pediatric eosinophilic esophagitis
Background: A new prepared oral viscous budesonide (PVB) has been effective in inducing clinical and histological remission in pediatric eosinophilic esophagitis (EoE). Aims: To evaluate the efficacy of a 12-week maintenance therapy on clinical, endoscopic, and histological remission using half of the dose used in the induction therapy. Methods: We prospectively enrolled pediatric patients with active EoE.